assess impairment of function before prescribing melatonin. The main preparation of melatonin prescribed is tablets (94%), followed by liquid (59%) then capsules (41%). Mostly (65%) slow release medication is given. The minimum dose of melatonin prescribed is 2 mg (range 0.5 mg–3 mg), maximum dose range (4–12 mg).

Practice varies in how often children are reviewed. Some (35%) review in the first 3–4 months, others 6 monthly (29%). Most (94%) clinicians offer at least yearly reviews. Routine trials off melatonin are offered by 65%. On average children stay 26 months on melatonin before withdrawal (range 6–120 months).

In comments Paediatrician gave views regarding the management of disrupted sleep, the need for good sleep hygiene support, which patient groups melatonin is best suited for and management of melatonin treatment.

Conclusions This survey has highlighted variability amongst Community Paediatricians in the East of England in certain areas of melatonin prescribing, possibly due to lack of uniform standards. With these results we are therefore creating a generic regional algorithm for initiating melatonin in children with disrupted sleep pattern which may form a platform for developing a melatonin prescription and sleep guideline for individual Organisation.

**Abstract G430(P) Figure 1** Current pathway

---

**G430(P) IS IT POSSIBLE TO HAVE HIGH STANDARDS PRACTICAL PATHWAY FOR AUTISM SPECTRUM DISORDER?**

A Tartihi, Community Paediatrics, Shropshire Community Health NHS Trust, Shrewsbury, UK

10.1136/archdischild-2015-308599.384

**Aims** Public awareness of Autism Spectrum Disorder (ASD) is increasing, as well as the demand for assessment. The implementation of high standards and practical pathway for assessment and diagnosis can be a challenge for many trusts including our trust. The aim was to reconstruct the current pathway by the trust to produce a practical pathway for assessment and diagnosis of ASD that meet the high standards of NICE guidelines and following the DSM-V criteria.

**Methods** Firstly the strengths and weaknesses of the current pathway have been identified. Secondly set up the essential elements of the future pathway defined by DSM-V criteria and NICE guidelines for ASD assessment and diagnosis. An estimated time scale was calculated based on clinic and administration time required.

**Results** Three essential elements for the assessment have been identified: A) comprehensive meeting with paediatrician, B) multisource observational reports and C) direct assessment. It was possible to incorporate in each step some elements of the NICE guidelines and DSM-V criteria to cover all the essential elements and criteria. Finally, a set of recommendations and suggested pathway for the assessment and diagnosis of ASD was produced. The estimated time to make a definitive outcome about ASD is possible within 240 min of clinician’s direct clinical and administration work.

See Figures 1 and 2

**Conclusion** It is essential for trusts to have a high standards and practical pathway for ASD diagnosis and assessment in line with NICE guidelines and DSM-V criteria. The current pathway was not satisfactory and a suggested practical pathway has been produced to meet the high standards of practice.
be reinforced by the integration of BBI risk assessment to induction of new community trainees. We plan to implement this in March 2015, and we aim to maintain and reinforce those changes, by continuous monitoring and service evaluation.

**INVESTIGATION INTO AN INCREASE IN PAEDIATRIC TUBERCULOSIS INCIDENCE IN GREATER MANCHESTER**

1ER Willis, 1CB Bell, 1C Murray, 2S Farrow, 3A Massarano, 4P McMaster, 5K Shankar, 5,6R McCann, 5,6M Petrovic. 1Paediatric Respiratory Medicine, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 2General Paediatrics, Bolton NHS Foundation Trust, Bolton, UK; 3General Paediatrics, Tameside Hospital NHS Foundation Trust, Manchester, UK; 4Paediatric Infectious Diseases, Pennine Acute Hospitals NHS Trust, Manchester, UK; 5Public Health, Public Health England, Manchester, UK; 6University of Manchester, Manchester, UK

**Aims**

During the period 2003/4–2009 there was an almost 3-fold increase in the incidence of tuberculosis (TB) in children in Greater Manchester (GM). The aim of this investigation was to understand the factors driving this increase, with a view to improving prevention and reversing the increasing trend.

**Methods**

Data were prospectively collected from paediatric TB cases diagnosed within GM between 1 January 2012 and 31 December 2013. Cases were GM residents <16 years at diagnosis. Information was collected from the parents/guardians of each case using a standardised proforma, where possible at the initial clinical consultation. At the end of the investigation period, teleconferences were held with each clinical service to assess the potential preventability in the UK setting of reported cases.

**Results**

60 TB cases were ascertained during the study period. Proforma were completed for 56/60. 57% were male. Age ranged from 0–15 years with 32% of cases under 5 years of age and 21% of the cases 15 years of age. Over half of the cases (31/56 (55%)) were UK-born, 9/56 (16%) were born in Pakistan and country of birth for the remainder was distributed across 11 different countries.

A total of 17 cases (30%) were judged to have been potentially preventable. Figure 1 shows the factors contributing to preventability by number of cases. 7/17 of the potentially preventable cases were UK-born.

**Conclusion**

A third of cases for whom data collection was completed were judged to have been potentially preventable. The two main themes that emerged were failure of the new entrant screening process and failure to be vaccinated with BCG vaccine despite being eligible. In order to reduce the burden of paediatric TB, it is important to ensure effective mechanisms are in place to maximise ascertainment of eligible new entrants to the UK. With regards to BCG vaccination, a review of arrangements across GM is currently underway.

**KIKUCHI DISEASE WITH MULTISYSTEM INVOLVEMENT: A CASE REPORT**

VK Sahu. Paediatric Medicine, KK Women’s and Children’s Hospital, Singapore

**Abstracts**

Arch Dis Child 2015;100(Suppl 3):A1–A288

---

**G432(P) INVESTIGATION INTO AN INCREASE IN PAEDIATRIC TUBERCULOSIS INCIDENCE IN GREATER MANCHESTER**

1ER Willis, 1CB Bell, 1C Murray, 2S Farrow, 3A Massarano, 4P McMaster, 5K Shankar, 5,6R McCann, 5,6M Petrovic. 1Paediatric Respiratory Medicine, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 2General Paediatrics, Bolton NHS Foundation Trust, Bolton, UK; 3General Paediatrics, Tameside Hospital NHS Foundation Trust, Manchester, UK; 4Paediatric Infectious Diseases, Pennine Acute Hospitals NHS Trust, Manchester, UK; 5Public Health, Public Health England, Manchester, UK; 6University of Manchester, Manchester, UK

10.1136/archdischild-2015-308599.386

**Methods**

Data were prospectively collected from paediatric TB cases diagnosed within GM between 1 January 2012 and 31 December 2013. Cases were GM residents <16 years at diagnosis. Information was collected from the parents/guardians of each case using a standardised proforma, where possible at the initial clinical consultation. At the end of the investigation period, teleconferences were held with each clinical service to assess the potential preventability in the UK setting of reported cases.

**Results**

60 TB cases were ascertained during the study period. Proforma were completed for 56/60. 57% were male. Age ranged from 0–15 years with 32% of cases under 5 years of age and 21% of the cases 15 years of age. Over half of the cases (31/56 (55%)) were UK-born, 9/56 (16%) were born in Pakistan and country of birth for the remainder was distributed across 11 different countries.

A total of 17 cases (30%) were judged to have been potentially preventable. Figure 1 shows the factors contributing to preventability by number of cases. 7/17 of the potentially preventable cases were UK-born.

**Conclusion**

A third of cases for whom data collection was completed were judged to have been potentially preventable. The two main themes that emerged were failure of the new entrant screening process and failure to be vaccinated with BCG vaccine despite being eligible. In order to reduce the burden of paediatric TB, it is important to ensure effective mechanisms are in place to maximise ascertainment of eligible new entrants to the UK. With regards to BCG vaccination, a review of arrangements across GM is currently underway.

**G433(P) KIKUCHI DISEASE WITH MULTISYSTEM INVOLVEMENT: A CASE REPORT**

VK Sahu. Paediatric Medicine, KK Women’s and Children’s Hospital, Singapore

10.1136/archdischild-2015-308599.387